Eli Lilly’s revenues
Eli Lilly (LLY) surpassed Wall Street analysts’ estimates and reported a 9.0% increase in its first-quarter top line to $5.7 billion, compared to the estimated revenues of ~$5.5 billion during the quarter.
The chart below compares the revenues of Eli Lilly since the first quarter of 2017 and its second-quarter estimates. Wall Street analysts forecast second-quarter revenues of $6.0 billion for 3.4% growth, compared to revenues of $5.8 billion in the second quarter of 2017.
Performance in Q1 2018
Eli Lilly (LLY) reported YoY (year-over-year) revenue growth of ~9.0% during the first quarter, driven by the strong performance of its new pharmaceutical products launched after 2014.
The US markets comprise more than 55.0% of Eli Lilly’s total revenues. The US markets reported revenues of $3.2 billion during the first quarter, representing 8.0% growth in YoY revenues compared to the first quarter of 2017.
This growth was driven by strong results by Jardiance, Trulicity, Taltz, Basaglar, and Verzenio. This growth was also influenced by higher realized prices for Cialis, Humalog, Basaglar, and Strattera, as well as strong performance of the companion animal products.
The international markets contribute more than 44.0% of Eli Lilly’s total revenues. The company’s international revenues reached $2.5 billion during the first quarter, representing 11.0% growth in YoY revenues compared to the first quarter of 2017. This growth was driven by the strong performance of Lartruvo, Jardiance, Olumiant, Taltz, and Trulicity, as well as by the favorable impact of foreign exchange during the quarter.
Eli Lilly’s net adjusted income increased to ~$1.4 billion during the first quarter, compared to net adjusted income of $1.0 billion during the first quarter of 2017. Its net adjusted income is expected to be ~$1.3 billion during the second quarter, compared to ~$1.2 billion during the second quarter of 2017.